The Italian Transthyretin Amyloidosis Web-Network

The study aims, by generating a large registry of patients with ATTR amyloidosis, including data at diagnosis and during follow up, to describe the natural history of ATTR amyloidosis in a real-world setting and to define and validate prognostic models, response criteria applicable at any point of the disease. The registry will also be used for data sharing and to allow the possibility of a close collaboration amongst the amyloidosis experts of the ARTC and all the physicians around the Country involved in the diagnosis and management of systemic amyloidosis. Thanks to the online registry, the diagnostic facility of the ARTC will be made available to requesting physicians.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

ATTR Amyloidosis Amyloidosis Immune System Diseases Immunoglobulin Light-chain Amyloidosis Immunoproliferative Disorders Lymphoproliferative Disorders Metabolic Diseases Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Nutritional and Metabolic Diseases Paraproteinemias Proteostasis Deficiencies

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

ASST Ovest Milanese - Ospedale di Legnano, Legnano, MI, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Suspected diagnosis of systemic and localized amyloidosis;
age .18 years;
ability to understand and willingness to sign an informed consent (patients who already sign informed consent for clinical data to be used in retrospective analyses will be accepted);
planned (or ongoing) follow-up at participating center.

Exclusion criteria

Diagnosis of light chain (AL) amyloidosis

Treatment and study plan

Primary outcomes

Establishing an online tool for data-sharing, available for health care providers

Time frame: 5 years

Different data (types type of organ involvement, biomarkers of organ damage, date of onset of symptoms, date of diagnosis, type of treatment (if any)) will be shared between the health-care professionals and the panel of experts.

Study contacts

Contact information is provided by the study sponsor or research team.

Paolo Milani, MD, PhD

CONTACT

[email protected]

+390382502994

Sponsors and collaborators

Lead sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Other

Registry information

Official study title

The Italian Transthyretin Amyloidosis Web-Network (ITA-WebNet)

Acronym: ITA-WebNet

Important dates

Study start: 2022
Primary completion: 2026
Study completion: 2027
First posted: Jul 6, 2022
Registry last updated: Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting